Argentina’s ANMAT preventively halted all production and sales by Trifarma S.R.L. and Ugal Farmacéutica S.A. and prohibited all their products nationwide, citing technical director and quality control deficiencies.

PHARMA REGULATION · MANUFACTURING ENFORCEMENT · SEPTEMBER 26, 2026 · ARGENTINA
Regulatory enforcement in Argentina’s pharmaceutical manufacturing sector has intensified since 2025, and two more laboratories are now caught in its path. On September 16, 2026, the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), Argentina’s national medicines and food safety regulator, ordered the preventive inhibition of the productive, quality-control and commercial activities of Laboratorio Trifarma S.R.L. and Ugal Farmacéutica S.A., according to dispositions 5865/2026 and 5870/2026 published in the Boletín Oficial.
The measures are sweeping in scope. ANMAT prohibited the use, commercialization, and distribution of all products of both firms across the entire Argentine territory, according to Infobae’s reporting of the dispositions. Both laboratories are now subject to administrative sanction proceedings (sumarios sanitarios). Under the dispositions, the firms may request reconsideration within 20 business days, appeal within 30 business days, or seek judicial review within 180 business days, per the same report.
Two Distinct Failure Modes, One Enforcement Outcome
The grounds for each inhibition differ, which is analytically significant. In the case of Trifarma S.R.L., registered at Bolivia 586 Bis in Rosario, province of Santa Fe, ANMAT cited the lack of a designated technical director and non-compliance linked to product registration, according to Infobae.
Ugal Farmacéutica S.A., located in Ramos Mejía, La Matanza, in the province of Buenos Aires, presents a different profile. Following an inspection by the Instituto Nacional de Medicamentos (INAME), ANMAT’s medicines quality institute, the agency cited critical and major deficiencies in the quality-management system, personnel, facilities, equipment, documentation, production and quality control, according to Infobae.
The distinction matters for downstream risk assessment. A missing technical director is a structural compliance gap. A production-condition deficiency is in principle remediable if the firm can demonstrate corrective action to ANMAT’s satisfaction. Whether Ugal Farmacéutica has initiated such a process has not been publicly disclosed.
A Pattern That Predates This Week
The September 16 actions do not occur in isolation. In January 2026, ANMAT disabled five more laboratories — Laboratorios Weltrap S.A., Laboratorio Incaico S.A., Carter Pack S.R.L., Pacemaker S.R.L., and LADECE S.A. — over irregularities in production, according to Infobae. In February 2026, ANMAT withdrew the habilitaciones of more than 60 drugstores and laboratories that were operating with lapsed certificates, according to Infobae.
The cumulative picture is one of systematic registry hygiene enforcement rather than purely reactive crisis management: a significant share of recent actions has targeted administrative failures, such as lapsed certificates or absent technical directors, rather than contamination events.
The fentanilo contamination crisis provides the clearest explanation for the shift in enforcement posture. A government audit covering October 2025 to January 2026, carried out by ANMAT’s Unidad de Auditoría Interna and obtained exclusively by Infobae, concluded that the control system ‘presents relevant weaknesses in its design and implementation.’ The audit found that 51 of 235 authorised pharmaceutical facilities (21.7%) had not been inspected for Good Manufacturing Practice (GMP) in more than five years, per Infobae. The audit was produced in the context of the contaminated-fentanilo case — in which federal judge Ernesto Kreplak is investigating 90 deaths and lasting complications in 44 patients linked to fentanilo contaminated with multidrug-resistant bacteria. ANMAT confirmed the definitive withdrawal of the habilitaciones of HLB Pharma Group S.A. and Laboratorios Ramallo S.A., the laboratories linked to the contaminated fentanilo, in April 2026, following the initial inhibition under Disposición 3158/2025, according to Infobae. The criminal matter remains pending resolution; no final judicial finding has been issued.
Trifarma and Ugal Farmacéutica are not alleged to have any connection to the fentanilo case. They are, however, operating under the inspection and enforcement regime that case produced.
What to Watch
- Whether Ugal Farmacéutica S.A. submits a corrective action plan to ANMAT and whether the agency deems it acceptable.
- The scope and speed of product withdrawal: both firms’ products are now prohibited nationwide — a logistical burden whose scale depends on each firm’s distribution footprint, which has not been publicly disclosed.
- Whether either firm seeks reconsideration or judicial review, and whether the sumarios sanitarios initiated against both laboratories end in permanent withdrawal of their habilitaciones or in a demonstration of compliance that allows operations to resume.
The deeper structural signal in this enforcement wave is that ANMAT’s registry is now being used as an active enforcement instrument rather than a passive record. Firms that allowed certificates to lapse, failed to maintain qualified technical directors, or accumulated unresolved inspection findings are discovering that the administrative tolerance that may have existed before 2025 has been withdrawn. With more than a fifth of authorised facilities uninspected for over five years, according to the audit reported by Infobae, further actions of this kind are plausible; no estimate of the number of firms still operating with latent compliance gaps has been published.
ANMAT Enforcement Actions — Argentina Pharmaceutical Sector
Why this is relevant
Patients
ANMAT’s nationwide prohibition on all products from Trifarma S.R.L. and Ugal Farmacéutica S.A. means patients relying on those products must switch to alternatives; the scale of any resulting shortage depends on each firm’s distribution footprint, which has not been publicly disclosed.
Industry
Both laboratories face operational halts under dispositions 5865/2026 and 5870/2026, with sumarios sanitarios initiated against each firm; both retain the right to seek reconsideration, appeal or judicial review.
Payers
Institutions and distributors holding stock from either firm cannot use or distribute the prohibited products, an unplanned logistical burden whose cost has not been quantified in publicly available documentation.
Litigation
The criminal investigation into 90 deaths and 44 cases of lasting complications linked to contaminated fentanilo, led by federal judge Ernesto Kreplak, remains pending resolution; Trifarma and Ugal Farmacéutica are unrelated to that case, but the enforcement regime it produced now governs all Argentine pharmaceutical manufacturers.
Sources: Infobae (16 September 2026) · Infobae (12 September 2026) · Infobae (10 April 2026) · Infobae (15 January 2026) · Infobae (20 February 2026)
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







